Brain nuclear factor kappa B is involved in the corticotropin-releasing factor-induced central activation of sympatho-adrenomedullary outflow in rats. 2008

Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
Department of Pharmacology, Graduate School of Medicine, Kochi University, Nankoku, Kochi 783-8505, Japan. okadas@kochi-u.ac.jp

Using urethane-anesthetized rats, we examined whether an activation of nuclear factor kappa B is involved in the corticotropin-releasing factor-induced increase in plasma levels of catecholamines. An intracerebroventricularly administered corticotropin-releasing factor (1.5 nmol/animal)-induced increase of plasma catecholamines was dose-dependently reduced by pyrrolidine dithiocarbamate (a nuclear factor kappa B antagonist) (1 and 9 nmol/animal, intracerebroventricularly) and SN50 (a peptide inhibiting nuclear factor kappa B translocation) (9 and 18 nmol/animal, intracerebroventricularly), while SN50M (an inactive control peptide for SN50, 19 nmol/animal, intracerebroventricularly) had no effect on the corticotropin-releasing factor-induced elevation of both catecholamines. Furthermore, the corticotropin-releasing factor-induced responses were also attenuated by rosiglitazone (a peroxisome proliferator-activated receptor-gamma agonist)(50 nmol/animal, intracerebroventricularly). These results suggest the involvement of brain nuclear factor kappa B in the corticotropin-releasing factor-induced central activation of the sympatho-adrenomedullary outflow in rats.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D009434 Neural Pathways Neural tracts connecting one part of the nervous system with another. Neural Interconnections,Interconnection, Neural,Interconnections, Neural,Neural Interconnection,Neural Pathway,Pathway, Neural,Pathways, Neural
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004837 Epinephrine The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS. Adrenaline,4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol,Adrenaline Acid Tartrate,Adrenaline Bitartrate,Adrenaline Hydrochloride,Epifrin,Epinephrine Acetate,Epinephrine Bitartrate,Epinephrine Hydrochloride,Epinephrine Hydrogen Tartrate,Epitrate,Lyophrin,Medihaler-Epi,Acetate, Epinephrine

Related Publications

Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
August 2003, European journal of pharmacology,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
September 2010, European journal of pharmacology,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
June 2000, European journal of pharmacology,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
January 1997, Life sciences,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
September 2003, European journal of pharmacology,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
September 1999, Japanese journal of pharmacology,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
December 2002, European journal of pharmacology,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
January 2016, Molecular and cellular biochemistry,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
November 1998, Neuroscience,
Shoshiro Okada, and Naoko Yamaguchi-Shima, and Takahiro Shimizu, and Junichi Arai, and Mieko Yorimitsu, and Kunihiko Yokotani
October 2002, European journal of pharmacology,
Copied contents to your clipboard!